Lincoln Pharmaceuticals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Lincoln Pharmaceuticals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 23% of its market value (net cash). Higher than 97% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 24.1 times by its yearly operating cash. Higher than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹100Over the last 3 years, every ₹100 of reported profit came with ₹100 of operating cash.
Lower than 53% of Healthcare companies in India.
Self-Funding Ratio
3.1×Over the last 3 years its own operating cash covered its investment spending (capex) 3.1 times.
Higher than 81% of Healthcare companies in India.
Cash Locked Ratio
₹22For every ₹100 of sales, ₹22 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹28 tied up three years earlier.
Less money tied up than 54% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹10Sales grew 31% in 3 years; of every extra ₹100 of sales, ₹10 became extra profit.
Lower than 68% of Healthcare companies in India.
Asset Productivity Ratio
+31% / +52%In 3 years sales changed by +31% while total assets changed by +52%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
24.1×Debt due within a year is covered 24.1 times by its yearly operating cash.
Higher than 86% of Healthcare companies in India.
Cash Cushion Ratio
+23%Cash, after subtracting all debt, equals 23% of its market value (net cash).
Higher than 97% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 82% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 84% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Lincoln Pharmaceuticals Limited owes ₹0.15 for every ₹1 it owns. Net profit rose 7% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
10.6Investors pay ₹10.6 for every ₹1 of Lincoln Pharmaceuticals Limited's yearly profit, lower than 96% of Healthcare companies in India.
P/B ratio
1.36The share price is 1.36 times Lincoln Pharmaceuticals Limited's book value per share, lower than 94% of Healthcare companies in India.
Market cap
₹1,027 CrThe total market value of all of Lincoln Pharmaceuticals Limited's shares at today's price (share price × number of shares), smaller than 80% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹758 CrWhat Lincoln Pharmaceuticals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹378.25Net worth divided by the number of shares. The share price of ₹512.70 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
12.7%Lincoln Pharmaceuticals Limited earned 12.7% on its shareholders' money over the last year, lower than 51% of Healthcare companies in India.
Owes vs Owns
0.15×Lincoln Pharmaceuticals Limited owes ₹0.15 for every ₹1 it owns (low), lower than 91% of Healthcare companies in India.
Dividend yield
0.32%Lincoln Pharmaceuticals Limited pays 0.32% of its share price as dividends a year, lower than 56% of dividend-paying Healthcare companies in India.
Revenue growth
+8%Revenue rose 8% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit growth
+7%Net profit rose 7% in the year to Mar 2026, and grew 6% a year on average over 3 years.
Profit margin
13.3%Lincoln Pharmaceuticals Limited keeps ₹13 of every ₹100 of revenue as net profit.
Cash quality
1.2×Cash from Lincoln Pharmaceuticals Limited's business was 1.2× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
205.2×Lincoln Pharmaceuticals Limited's operating profit covered its interest costs 205.2 times in the year to Mar 2026.
Cash vs debt
Net cashLincoln Pharmaceuticals Limited held ₹236 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Lincoln Pharmaceuticals Limited's P/E ratio?
Investors pay ₹10.6 for every ₹1 of Lincoln Pharmaceuticals Limited's yearly profit, lower than 96% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Lincoln Pharmaceuticals Limited: ₹1,027 Cr ÷ ₹758 Cr (31 Mar 2026) = 1.4.
What is Lincoln Pharmaceuticals Limited's return on equity?
Lincoln Pharmaceuticals Limited earned 12.7% on its shareholders' money over the last year, lower than 51% of Healthcare companies in India.
How much does Lincoln Pharmaceuticals Limited owe compared with what it owns?
Lincoln Pharmaceuticals Limited owes ₹0.15 for every ₹1 it owns (low), lower than 91% of Healthcare companies in India.
Does Lincoln Pharmaceuticals Limited pay a dividend?
Yes. Lincoln Pharmaceuticals Limited pays 0.32% of its share price as dividends a year, lower than 56% of dividend-paying Healthcare companies in India.
Is Lincoln Pharmaceuticals Limited's revenue growing?
Revenue rose 8% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.